GHRP-2 · Growth-hormone-releasing peptide research context

GHRP-2 (growth-hormone-releasing peptide-2), also referred to in the literature as pralmorelin, is a synthetic peptide studied as a growth-hormone secretagogue. It is described in research settings as a small synthetic molecule investigated for its interaction with signaling pathways connected to the pituitary gland.

This page is provided for educational purposes only. It does not describe dosing, does not make treatment or outcome claims, and does not present GHRP-2 as a therapy for any condition. Whether any peptide is appropriate for an individual is a determination made only by a licensed provider following a confidential intake and review.

In the research literature, GHRP-2 is characterized as a ligand that interacts with the growth-hormone secretagogue receptor (GHS-R), the same receptor family associated with the hormone ghrelin. Investigators have discussed this interaction in the context of signaling from the pituitary gland in controlled study models.

Mechanistic descriptions in the literature are drawn from laboratory and early-stage research and should not be interpreted as evidence of clinical benefit. The relationship between any described mechanism and real-world outcomes in people has not been established here and remains a matter for qualified researchers and licensed providers to evaluate.

Regulatory status varies by country and can change. GHRP-2 is studied in research contexts, and its legal and regulatory classification differs across jurisdictions. Nothing on this page should be read as a claim of approval, safety, or efficacy.

Education only · provider review required. A licensed provider determines whether any peptide is appropriate for an individual after a confidential intake.